COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A DISCRETE EVENT SIMULATION ECONOMIC MODELLING STUDY

被引：2
|
作者：
Men, P. [1 ]
Liu, T. [2 ]
Chu, Y. [3 ]
Zhai, S. [1 ]
机构：
[1] Peking Univ, Hosp 3, Dept Pharm, Beijing, Peoples R China
[2] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
[3] Boehringer Ingelheim China Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.497
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB45
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [31] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [32] Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
    McGuire, D.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    Von Eynatten, M.
    Johansen, O-E.
    Elsasser, U.
    Pocock, S.
    Fitchett, D.
    Jamal, W.
    Hantel, S.
    Lund, S. S.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3875 - 3875
  • [33] Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa
    de Beer, Janetta Catharina
    Snyman, Jacques
    Ker, James
    Miller-Janson, Helen
    Stander, Marthinus
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 33 : 91 - 98
  • [34] Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
    Feng, Tianyu
    Zheng, Zhou
    Gao, Shang
    Xu, Jiaying
    Cao, Pen
    Jia, Huanhuan
    Yu, Xihe
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Linda J Cobiac
    Anne Magnus
    Jan J Barendregt
    Rob Carter
    Theo Vos
    [J]. BMC Public Health, 12
  • [36] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Li, Te
    Wan, Xu
    Ma, Jin
    Wu, Bin
    [J]. ADVANCES IN THERAPY, 2018, 35 (12) : 2214 - 2223
  • [37] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Cobiac, Linda J.
    Magnus, Anne
    Barendregt, Jan J.
    Carter, Rob
    Vos, Theo
    [J]. BMC PUBLIC HEALTH, 2012, 12
  • [38] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Te Li
    Xu Wan
    Jin Ma
    Bin Wu
    [J]. Advances in Therapy, 2018, 35 : 2214 - 2223
  • [39] COST-EFFECTIVENESS OF ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN CHINESE PATIENTS WITH DIABETES
    Jiang, M.
    Li, P.
    Zheng, X.
    Deng, J.
    Zhao, M.
    Fang, Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S129 - S129
  • [40] COST-EFFECTIVENESS ANALYSIS OF ULINASTATIN FOR PATIENTS UNDERGOING HEPATECTOMY: A DISCRETE EVENT SIMULATION MODEL
    Lin, Z.
    Zhou, J.
    Yang, Q.
    Xing, R.
    Li, M.
    Yu, Q.
    Xuan, J. W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A635 - A636
12345